APOE gene ε4 allele (388C-526C) effects on serum lipids and risk of coronary artery disease in southern Chinese Hakka population

Qinghua Liu1,2,3 | Heming Wu2,3 | Zhikang Yu2,3 | Qingyan Huang2,3 | Zhixiong Zhong2,3

1Center for Pathological Diagnostics, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, China
2Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, China
3Guangdong Provincial Engineering and Technology Research Center for Molecular Diagnostics of Cardiovascular Diseases, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, Meizhou, China

Correspondence
Zhixiong Zhong, Center for Precision Medicine, Guangdong Provincial Key Laboratory of Precision Medicine and Clinical Translational Research of Hakka Population, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences, No 63 Huangtang Road, Meijiang District, Meizhou 514031, China.
Email: zhongzhixiong01@126.com

Abstract
Objective: To analyze the relationship of Apolipoprotein E (APOE) and solute carrier organic anion transporter family member 1B1 (SLCO1B1) gene polymorphisms with coronary artery disease (CAD).

Methods: 1,129 CAD patients and 1,014 non-CAD controls were included in the study, and relevant information and medical records were collected. The single-nucleotide polymorphisms (SNPs) were analyzed, including rs429358, rs7412 in APOE gene and rs2306283, rs4149056 in SLCO1B1 gene.

Results: The CAD patients’ average age was 66.3 ± 10.7 years, while 65.5 ± 12.0 years in controls. The frequencies of APOE allele ε3, ε4, and ε2 were 83.01%, 10.08%, and 6.91% respectively. There were statistically significant differences in genotype ε3/ε4 (χ² = 8.077, p = 0.005) in CAD patients compared with the controls. The SLCO1B1 genotype *1b/*1b and haplotype *1b showed the highest frequency in the study sample. Moreover, ε4 carriers had significantly lower HDL-C, Apo-A1 levels than ε3 carriers among CAD patients, while ε2 carriers showed lower LDL-C, Apo-B level, and higher Apo-A1/Apo-B level than ε3 and ε4 carriers. In controls, ε2 carriers showed lower LDL-C and Apo-B level, higher Apo-A1, and Apo-A1/Apo-B level than ε4 carriers. Logistic regression analysis showed that high LDL-C and Apo-B level, low HDL-C level, smoking, and the ε4 allele were risks for the presence of CAD.

Abbreviations: Apo-A1, apolipoprotein A1; Apo-B, apolipoprotein B; APOE, apolipoprotein E; HDL-C, high-density lipoprotein-cholesterol; LDL-C, low-density lipoprotein-cholesterol; SLCO1B1, solute carrier organic anion transporter family member 1B1; TC, total cholesterol; TG, triglyceride.

This is an open access article under the terms of the Creative Commons Attribution-NonCommercial License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited and is not used for commercial purposes.
© 2021 The Authors. Journal of Clinical Laboratory Analysis published by Wiley Periodicals LLC.
1 | INTRODUCTION

Coronary artery disease (CAD) is a kind of coronary artery atherosclerosis, narrowing or occlusion of vascular lumen, resulting in myocardial ischemia and hypoxia or necrosis caused by heart disease, and is one of the main causes of death in developed and developing countries.1,2 CAD is an atherosclerotic inflammatory disease characterized by stable angina, unstable angina, myocardial infarction, or sudden cardiac death.3 Smoking, drinking, obesity, hypertension, bad living habits, and genetic factors are considered to be closely related to the incidence of CAD. So far, more than 60 genetic variants have been confirmed to be associated with increased susceptibility to CAD using genome-wide association studies (GWAS).4 Previous studies have shown that genes related to CAD mainly include genes related to vascular structure and function, lipid metabolism, and inflammatory cytokines.5-7

Apolipoprotein E (ApoE) is one of the apolipoproteins of chylomicron, high-density lipoprotein-cholesterol (HDL-C), low-density lipoprotein-cholesterol (LDL-C), and very low-density lipoprotein-cholesterol (VLDL-C), which plays an important role in regulating lipoprotein metabolism. ApoE is a multifunctional protein that plays an important role in lipid metabolism by binding to LDL receptors and mediating the removal of chylomicron and VLDL from serum.8 ApoE (OMIM 107741) is the gene that codes for ApoE, which its cytotgenic location is 19q13.32. There are 2 common single-nucleotide polymorphisms (SNPs) in APOE gene: rs429358 (388T > C) and rs7412 (526C > T). And 3 alleles (ɛ2(388T-526T), ɛ3(388T-526C), and ɛ4(388C-526C)) and 6 genotypes (ɛ2/ɛ2, ɛ2/ɛ3, ɛ2/ɛ4, ɛ3/ɛ3, ɛ3/ɛ4, and ɛ4/ɛ4) can be formed by the 2 SNPs.9 ApoE2, -E3, and -E4 are 3 major isoforms of human ApoE, which coded by 3 alleles (epsilon (ɛ) 2, 3, and 4).

Solute carrier organic anion transporter family member 1B1 (SLCO1B1) is an intake transporter for the transport of substances from the blood to the liver. SLCO1B1 is encoded by SLCO1B1 gene (located on chromosome 12p12.1). The rs2306283 (388A > G) and rs4149056 (521T > C) are 2 common SNPs in SLCO1B1 gene.10,11 4 haplotypes can be formed by the two SNPs: *1a (388A-S521T), *1b (388G-S521T), *5 (388A-S521C), and *15 (388G-S521C).12-14 To date, most studies on SLCO1B1 have focused on the effect of SLCO1B1 polymorphisms on the pharmacokinetics, efficacy and side effects of glucose-lowering drugs, statins, and antitumor drug.15,16

APOE and SLCO1B1 gene polymorphisms are associated with the efficacy and side effects of statin lipid-lowering drugs, and also affect the occurrence and development of some diseases. However, most patients with CAD will have lipid metabolism dysfunction. Whether these SNP sites are associated with the susceptibility to CAD has not been systematically reported. Although some studies have analyzed the relationship between APOE gene polymorphisms and the risk of cardiovascular and cerebrovascular diseases, the results are inconsistent in different regions and populations. In this study, the relationship between SLCO1B1 and APOE polymorphisms and CAD was analyzed in southern Chinese Hakka population.

2 | MATERIALS AND METHODS

2.1 | Population samples

A total of 2,143 subjects were recruited from Meizhou People's Hospital (Huangtang Hospital), China, between September 2016 and May 2020, including 1129 CAD patients and 1014 individuals with non-CAD as controls. The diagnosis of CAD was based on the American College of Cardiology/American Heart Association (ACC/AHA) classification. The patients have chest pain, ischemic changes in electrocardiograph (ECG), and increased myocardial enzymes by clinical evaluation and more than 50% reduction of coronary artery diameter in at least one of the major arteries proved by coronary angiography. Patients with severe liver, kidney, brain diseases, malignant tumors, and hematological diseases were excluded. Information recorded included demographic data (age, sex), history of major chronic diseases (hypertension, diabetes), smoking history, and alcohol consumption history. This study was performed in accordance with the ethical standards laid down in the updated version of the 1964 Declaration of Helsinki and approved by the Human Ethics Committees of Meizhou People's Hospital (Clearance No.: 2016-A-29). Informed consent was obtained from the patients or their families, and participants’ privacy was carefully protected.

2.2 | Serum lipid measurements

About 3ml of blood was taken from each subject, serum was rapidly separated and tested, and samples that could not be immediately tested were stored at −80°C. Serum lipid levels of samples were evaluated in the Olympus AU5400 system (Olympus Corporation, Tokyo, Japan), test indicators including total cholesterol (TC),...
triglyceride (TG), LDL-C, HDL-C, apolipoprotein B (Apo-B), and apolipoprotein A1 (Apo-A1). Serum lipid levels were measured by the corresponding detection methods following the manufacturers’ instructions.

2.3 DNA extraction and genotyping assay

Genomic DNA was extracted from whole blood using a TiAnamp Blood DNA Kit (Tiangen, Beijing, China) according to the manufacturer’s instructions. SLCO1B1 and APOE gene polymorphisms were detected by TaqMan probe fluorescent PCR method through different channels in the reaction system with different primers and probes combinations (Youzhiyou Medical Technology Co., Ltd, Hubei, China). PCR was used to amplify the target fragments using the Roche LightCycler 480 II system: initial denaturation at 95°C for 5 min, followed by 40 cycles of denaturation at 95°C for 15s, annealing, and extension at 60°C for 1 min. FAM (SLCO1B1*1b 388A, SLCO1B1*5 521T, ApoE2 526C, ApoE4 388T), VIC (SLCO1B1*1b 388G, SLCO1B1*5 521C, ApoE2 526T, and ApoE4 388C) and ROX (internal standard) fluorescence signals were collected.

2.4 Statistical analysis

SPSS statistical software version 21.0 (IBM Inc., State of New York, USA) was used for data analysis. Continuous variable data are represented by mean ± SD and analyzed using Student’s t test or the Mann-Whitney U test. The Chi-square test was used for analyzing categorical variables, which were presented as percentages. Logistic regression analysis was used to evaluate the interactions between SLCO1B1 and APOE polymorphisms and various factors (age, gender, smoking history, drinking history, prevalence of hypertension, and diabetes, etc.) in CAD. p < 0.05 was considered statistically significant.

3 RESULTS

3.1 Population characteristics

In this study, there were 2,143 subjects (65.9 ± 11.4 years), with the youngest is 20 years, the oldest is 97 years, consisted of 1,129 CAD patients (694 (61.47%) males and 435 (38.53%) females), and 1014 non-CAD controls (595 (58.68%) males and 419 (41.32%) females). The CAD patients’ average age was 66.3 ± 10.7 years, while 65.5 ± 12.0 years in controls. There were statistically significant differences in percentage of smokers (CAD patients vs. non-CAD controls: 31.62% vs. 19.72%, p < 0.001), TG level (1.949 ± 1.573 mmol/L vs. 1.642 ± 1.184 mmol/L, p < 0.001), HDL-C level (1.237 ± 0.318 mmol/L vs. 1.307 ± 0.357 mmol/L, p < 0.001), and Apo-B level (0.898 ± 0.284 g/L vs. 0.861 ± 0.270 g/L, p = 0.002) between the patients and controls, while no statistically significant differences in age, TC, LDL-C, Apo-A1, gender composition ratio, and percentage of alcoholics, hypertension, and diabetes (Table 1).

3.2 Genotype and haplotype frequencies of APOE gene

The frequencies of genotype ε3/ε3, ε3/ε4, ε2/ε3, ε2/ε4, ε4/ε4, and ε2/ε2 were 69.16%, 16.61%, 11.11%, 1.21%, 1.17%, and 0.75%, respectively, in all subjects. The frequencies of allele ε3, ε4, and ε2 were 83.01%, 10.08%, and 6.91% respectively. The genotype distribution in controls was consistent with Hardy-Weinberg equilibrium ($\chi^2 = 0.515, p = 0.992$). The results showed that the most common APOE genotype was ε3/ε3, and the frequencies of alleles in order from high to low were ε3, ε4, and ε2 (Table 2).

There were statistically significant differences in genotype ε3/ε4 ($\chi^2 = 8.077, p = 0.005$) in CAD patients compared with the controls. The frequency of allele ε4 ($\chi^2 = 8.931, p = 0.003$) showed statistically significant difference in the patients compared with controls. The differences in other genotypes (ε2/ε2, ε2/ε3, ε2/ε4, ε3/ε3, and ε4/ε4) and alleles (ε2 and ε3) of APOE gene between the CAD patients and the controls were not statistically significant (all p > 0.05) (Table 2).

3.3 Genotype and haplotype frequencies of SLCO1B1 gene

Of all the participants, the frequencies of genotype *1b/*1b, *1a/*1b, *1a/*15, *1a/*1a, *15/*15, and *1a/*5 were 39.06%, 31.64%, 15.59%, 6.16%, 5.83%, 1.63%, and 0.20%, respectively. The frequencies in the CAD patients were 38.35%, 31.36%, 16.56%, 5.76%, 6.20%, 1.77%, and 0%, and 39.84%, 31.95%, 14.50%, 6.61%, 5.42%, 1.48%, and 0.20% in the controls. The genotype distribution in controls was consistent with Hardy-Weinberg equilibrium ($\chi^2 = 1.397, p = 0.968$). There were no statistically significant differences in the frequencies of these genotypes between CAD patients and controls. The *1b haplotype (62.67%) presented the highest frequency, followed by haplotype *1a (24.78%), *15 (12.51%), and *5 (0.05%). The frequencies of SLCO1B1 haplotypes between CAD patients and controls showed no statistically significant differences (Table 3).

3.4 Relationships between serum lipid levels and APOE alleles, SLCO1B1 genotypes and logistic regression analysis of the risks for CAD

Relationships between APOE alleles (ε2, ε3, and ε4) and serum lipid levels were analyzed. Because the ε2 and ε4 alleles play opposite roles in lipid metabolism, subjects with both ε2 and ε4 alleles (ε2/ε4 genotype) were excluded (n = 26, 15 patients, and 11 controls). In CAD patients, ε4 carriers had significantly lower HDL-C
Atherosclerosis is an important pathophysiological basis of CAD. The main cause of CAD is the formation of atherosclerotic plaque, and the increase of serum lipid level is the main factor of the formation of atherosclerotic plaque.\textsuperscript{22,23} ApoE is a major lipid-binding protein that serves as a carrier for chylomicron, HDL-C, LDL-C, and VLDL-C.\textsuperscript{24} However, the results on the relationship between APOE gene polymorphisms and serum lipid level are not consistent. Rajesh Chaudhary et al evaluated the effect of APOE on lipids has shown that carriers of the \( \epsilon 2 \) allele have lower TC level and higher TG level, while carriers of the \( \epsilon 4 \) allele have higher TC and LDL levels.\textsuperscript{25} Another study showed that the APOE \( \epsilon 4 \) allele is associated with higher serum lipid levels, whereas the \( \epsilon 2 \) allele is associated with the lower levels.\textsuperscript{26} A Pablos-Méndez et al reported that the presence of \( \epsilon 2 \) has been associated with lower LDL-C level but with no influence on the HDL-C level.\textsuperscript{27}

In the present study, \( \epsilon 4 \) carriers had significantly lower HDL-C and Apo-A1 levels than \( \epsilon 3 \) carriers among CAD patients, while \( \epsilon 2 \) carriers showed lower LDL-C, Apo-B levels, and higher Apo-A1/Apo-B level than \( \epsilon 3 \) and \( \epsilon 4 \) carriers. In controls, \( \epsilon 2 \) carriers showed lower LDL-C and Apo-B, higher Apo-A1 and Apo-A1/Apo-B (all \( p < 0.05 \)) than \( \epsilon 4 \) carriers (Table 4).

Logistic regression analysis was performed to determine independent predictors for CAD. The results indicated significantly higher risks of CAD in the presence of high LDL-C level (adjusted OR 2.885, 95% CI 2.016–4.129, \( p < 0.001 \)), and Apo-B level (adjusted OR 1.680, 95% CI 1.296–2.178, \( p < 0.001 \)), low HDL-C level (adjusted OR 0.459, 95% CI 0.498–0.839, \( p = 0.005 \)), smoking (adjusted OR 2.043, 95% CI 1.619–2.577, \( p < 0.001 \)), and the \( \epsilon 4 \) allele (adjusted OR 1.354, 95% CI 1.068–1.717, \( p = 0.012 \)) (Table 5).

4 | DISCUSSION

CAD is a common chronic disease in the world. In recent years, the incidence of CAD has gradually increased, and it has become one of the main causes of death.\textsuperscript{17,18} The incidence of CAD is increasing among younger individuals.\textsuperscript{19} The relationship between gene polymorphisms and genetic susceptibility to CAD has been the focus of clinical and epidemiological studies in recent years. Many studies have shown that the etiologies of CAD are complex, including genetic and environmental factors.\textsuperscript{4,20,21} The relationship between genetic polymorphisms of APOE and SLCO1B1 and CAD in Hakka population was analyzed in this study.
### TABLE 2 Genotypes and alleles distribution of APOE gene in CAD patients and control participants

| Genotypes | ε2/ε2 | ε2/ε3 | ε2/ε4 | ε3/ε3 | ε3/ε4 | ε4/ε4 |
|-----------|-------|-------|-------|-------|-------|-------|
| All subjects (n = 2143) | 16(0.75%) | 238(11.11%) | 26(1.21%) | 1482(69.16%) | 356(16.61%) | 25(1.17%) |
| Patients (n = 1129) | 6(0.59%) | 125(12.33%) | 11(1.08%) | 718(70.81%) | 144(14.20%) | 10(0.99%) |
| Controls (n = 1014) | 10(0.98%) | 113(10.01%) | 15(1.43%) | 664(65.67%) | 202(19.78%) | 10(0.99%) |

| Alleles | ε2 | ε3 | ε4 |
|---------|----|----|----|
| All subjects (n = 4286) | 296(6.91%) | 3558(83.01%) | 432(10.08%) |
| Patients (n = 2258) | 148(6.55%) | 1853(82.06%) | 257(11.38%) |
| Controls (n = 2028) | 148(7.30%) | 1705(84.07%) | 175(8.63%) |

p Values (Patients vs controls) | 0.463(χ² = 0.623) | 0.098(χ² = 2.909) | 0.695(χ² = 2.466) | 0.005(χ² = 8.077) | 0.548(χ² = 0.543) |

Note: Numbers in parentheses are percentages.
**TABLE 3** Genotypes and alleles distribution of SLCO1B1 gene in CAD patients and control participants.

| Genotypes       | *15/*15 | *1a/*15 | *1a/*1a | *1a/*1b | *1a/*5 | *1b/*15 | *1b/*1b |
|------------------|---------|---------|---------|---------|--------|---------|---------|
| All subjects(n = 2143) | 35 (1.63%) | 132 (6.16%) | 125 (5.83%) | 678 (31.64%) | 2 (0.09%) | 334 (15.59%) | 837 (39.06%) |
| Patients(n = 1129) | 20 (1.77%) | 65 (5.76%) | 70 (6.20%) | 354 (31.36%) | 0 (0) | 187 (16.56%) | 433 (38.35%) |
| Controls(n = 1014) | 15 (1.48%) | 67 (6.61%) | 55 (5.42%) | 324 (31.95%) | 2 (0.20%) | 147 (14.50%) | 404 (39.84%) |

| Alleles | *15 | *5 | *1a | *1b |
|---------|-----|----|-----|-----|
| All subjects(n = 4286) | 536 (12.51%) | 2 (0.05%) | 1062 (24.78%) | 2686 (62.67%) |
| Patients(n = 2258) | 292 (12.93%) | 0 (0) | 559 (24.76%) | 1407 (62.31%) |
| Controls(n = 2028) | 244 (12.03%) | 2 (0.10%) | 503 (24.80%) | 1279 (63.07%) |

| p Values (Patients vs controls) | 0.614 (χ² = 0.284) | 0.420 (χ² = 0.668) | 0.461 (χ² = 0.586) | 0.780 (χ² = 0.088) | 0.224 (χ² = 2.229) | 0.190 (χ² = 1.734) | 0.506 (χ² = 0.498) |

Note: Numbers in parentheses are percentages.

**TABLE 4** Relationships between serum lipid level and APOE allele in CAD patients and control participants.

| Serum lipid level | CAD patients (n = 1114) | Controls (n = 1003) |
|-------------------|-------------------------|---------------------|
|                   | ε2 (n = 123) | ε3 (n = 764) | ε4 (n = 227) | p Values | ε2 (n = 131) | ε3 (n = 718) | ε4 (n = 154) | p Values |
| TG, mmol/L | 2.191 ± 1.500 | 1.907 ± 1.587 | 1.873 ± 1.441 | 0.137 | 1.857 ± 1.2420 | 1.640 ± 1.2290 | 1.424 ± 0.785* | 0.008 |
| TC, mmol/L | 4.815 ± 1.268 | 4.965 ± 1.170 | 4.953 ± 1.384 | 0.454 | 5.001 ± 1.423 | 4.938 ± 1.178 | 4.986 ± 1.042 | 0.802 |
| HDL-C, mmol/L | 1.218 ± 0.271 | 1.255 ± 0.3220 | 1.193 ± 0.321* | 0.029 | 1.335 ± 0.351 | 1.304 ± 0.365 | 1.300 ± 0.326 | 0.637 |
| LDL-C, mmol/L | 2.498 ± 0.872*◊ | 2.764 ± 0.828 | 2.792 ± 0.980 | 0.004 | 2.672 ± 0.9650 | 2.794 ± 0.861 | 2.884 ± 0.767 | 0.117 |
| Apo-A1, g/L | 1.157 ± 0.270 | 1.156 ± 0.2780 | 1.106 ± 0.266* | 0.047 | 1.227 ± 0.3370 | 1.171 ± 0.340 | 1.134 ± 0.299 | 0.065 |
| Apo-B, g/L | 0.829 ± 0.285*◊ | 0.902 ± 0.269 | 0.925 ± 0.314 | 0.008 | 0.880 ± 0.2950 | 0.860 ± 0.265 | 0.900 ± 0.262 | 0.044 |
| Apo-A1/ Apo-B | 1.520 ± 0.526*◊ | 1.380 ± 0.481 | 1.308 ± 0.469 | <0.001 | 1.654 ± 0.697*◊ | 1.477 ± 0.613 | 1.342 ± 0.482 | <0.001 |

Note: p Value shows the differences compared between groups (ε2, ε3, and ε4).
* p < 0.05 versus corresponding ε3 group.
◊ p < 0.05 versus corresponding ε4 group.
There are several strengths of this study. This is the first systematic study of the association between CAD and APOE and SLCO1B1 gene polymorphisms in Hakka population. The lifestyle, lipid levels, APOE, and SLCO1B1 gene polymorphisms were included in the analysis and have excluded the influence of related confounding factors on the results. There are some limitations to this study. First, CAD is a multifactorial disease caused by genetic and environmental factors. As a retrospective case-control analysis, some records in this study could not be traced and verified, limiting the assessment of potential gene-environment interactions. For example, the study could not trace whether patients were taking statins, lipid-lowering drugs, or traditional Chinese medicine prior to admission. Second, although the sample size included in this study is enough to draw reliable conclusion, the sample size is not particularly large, and the possibility of some deviation in the results cannot be ruled out.

There are several strengths of this study. This is the first systematic study of the association between CAD and APOE and SLCO1B1 gene polymorphisms in Hakka population. The lifestyle, lipid levels, APOE, and SLCO1B1 gene polymorphisms were included in the analysis and have excluded the influence of related confounding factors on the results. There are some limitations to this study. First, CAD is a multifactorial disease caused by genetic and environmental factors. As a retrospective case-control analysis, some records in this study could not be traced and verified, limiting the assessment of potential gene-environment interactions. For example, the study could not trace whether patients were taking statins, lipid-lowering drugs, or traditional Chinese medicine prior to admission. Second, although the sample size included in this study is enough to draw reliable conclusion, the sample size is not particularly large, and the possibility of some deviation in the results cannot be ruled out.

5 CONCLUSIONS

The present study suggests that APOE ε4 allele has effects on serum lipids and may be associated with susceptibility to CAD in southern Chinese Hakka population. SLCO1B1 c.388A > G and c.521T > C may have no relationship between gene polymorphisms and the incidence of CAD. It indicated that the APOE SNPs rs429358 and rs7412 are associated with CAD, but not SNPs rs2306283 and rs4149056 of SLCO1B1 gene. Therefore, APOE genotyping and serum lipids testing may be useful to identify individuals at risk for CAD.

ACKNOWLEDGEMENTS

The author would like to thank other colleagues who were not listed in the authorship of Center for Precision Medicine, Meizhou People’s Hospital (Huangtang Hospital), Meizhou Academy of Medical Sciences for their helpful comments on the manuscript.

CONFLICT OF INTEREST

The authors declare that they have no competing interests.

AUTHORS CONTRIBUTIONS

Zhixiong Zhong and Heming Wu designed the study. Qinghua Liu, Heming Wu, and Qingyan Huang collected clinical data. Heming Wu, Zhihang Yu, and Qingyan Huang analyzed the data. Heming Wu and Qinghua Liu prepared the manuscript. All authors were responsible for critical revisions, and all authors read and approved the final version of this work.

| Variables | Alleles/Genotypes | Unadjusted values | Adjusted values |
|-----------|------------------|------------------|----------------|
|           | p Value | OR    | 95% CI | p Value | Adjusted OR | 95% CI |
| Gender (male) | 0.180 | 0.888 | 0.746–1.057 | 0.121 | 1.181 | 0.957–1.456 |
| Smoking | <0.001 | 1.863 | 1.524–2.276 | <0.001 | 2.043 | 1.619–2.577 |
| TG | <0.001 | 1.191 | 1.108–1.281 | 0.323 | 0.953 | 0.866–1.049 |
| TC | 0.880 | 0.995 | 0.927–1.067 | 0.058 | 0.767 | 0.582–1.009 |
| HDL-C | <0.001 | 0.542 | 0.419–0.700 | 0.005 | 0.459 | 0.498–0.839 |
| LDL-C | 0.166 | 0.933 | 0.845–1.029 | <0.001 | 2.885 | 2.016–4.129 |
| Apo-A1 | 0.046 | 0.752 | 0.568–0.996 | 0.293 | 0.788 | 0.505–1.229 |
| Apo-B | 0.002 | 1.658 | 1.211–2.269 | <0.001 | 1.680 | 1.296–2.178 |
| APOE allele | | | | | |
| ε2 carrier | 0.154 | 0.826 | 0.636–1.074 | 0.141 | 0.811 | 0.614–1.072 |
| ε4 carrier | 0.003 | 1.411 | 1.128–1.767 | 0.012 | 1.154 | 1.068–1.717 |
| SLCO1B1 388 genotype | | | | | |
| A/G + G/G | 0.436 | 0.865 | 0.601–1.245 | 0.357 | 0.831 | 0.560–1.232 |
| A/A + A/G | 0.711 | 0.968 | 0.815–1.150 | 0.576 | 0.947 | 0.784–1.145 |
| SLCO1B1 521 genotype | | | | | |
| T/C + C/C | 0.514 | 1.069 | 0.874–1.307 | 0.690 | 1.046 | 0.840–1.301 |
| T/T + T/C | 0.590 | 0.830 | 0.423–1.631 | 0.737 | 0.883 | 0.429–1.820 |

Abbreviations: CI, confidence interval; LDL-C, low-density lipoprotein-cholesterol; OR, odds ratio.

a ε2/ε2 plus ε2/ε3, reference genotype: ε3/ε3 plus ε3/ε4 plus ε4/ε4.
b ε3/ε3 plus ε4/ε4, reference genotype: ε2/ε2 plus ε2/ε3 plus ε3/ε3.
c Reference genotype: SLCO1B1 388 A/A.
d Reference genotype: SLCO1B1 388 G/G.
e Reference genotype: SLCO1B1 521 T/T.
f Reference genotype: SLCO1B1 521 C/C.
DATA AVAILABILITY STATEMENT
The data that support the findings of this study are available from the corresponding author upon reasonable request.

ORCID
Heming Wu https://orcid.org/0000-0002-1876-9585
Zhixiong Zhong https://orcid.org/0000-0002-9997-5339

REFERENCES
1. Global, regional, and national age-sex specific all-cause and cause-specific mortality for 240 causes of death, 1990–2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet. 2015;385(9963):117-171.
2. Bauersachs R, Zeymer U, Brière JB, Marre C, Bowrin K, Huelsebeck M. Burden of coronary artery disease and peripheral artery disease: a literature review. Cardiovasc Ther. 2019;2019:8295054.
3. Álvarez-Alvarez MM, Zanetti D, Carreras-Torres R, Moral P. A survey of sub-Saharan gene flow into the Mediterranean at risk loci for coronary artery disease. Eur J Hum Genet. 2017;25(4):472-476.
4. McPherson R, Tybjærg-Hansen A. Genetics of coronary artery disease. Circ Res. 2016;118(4):564-578.
5. Li Y, Wang DW, Chen Y, et al. Genome-wide association and functional studies identify SCML4 and THSD7A as novel susceptibility genes for coronary artery disease. Arterioscler Thromb Vasc Biol. 2018;38(4):964-975.
6. Mirhafez SR, Avan A, Khatamianfar S, et al. There is an association between a genetic polymorphism in the ZNF259 gene involved in lipid metabolism and coronary artery disease. Gene. 2019;70:80-85.
7. Tabaei S, Motallebezhad M, Tabaei SS. Systematic review and meta-analysis of association of polymorphisms in inflammatory cytokine genes with coronary artery disease. Inflamm Med. 2020;2020(10):1001-1013.
8. Blum CB. Type III hyperlipoproteinemia: still worth considering? Prog Cardiovasc Dis. 2016;59(2):119-124.
9. Seripa D, D’Onofrio G, Panza F, Cascavilla L, Masullo C, Pilotta A. The genetics of the human APOE polymorphism. Rejuvenation Res. 2011;14(5):491-500.
10. Nies AT, Niemi M, Burk O, et al. Genetics is a major determinant of expression of the human hepatic uptake transporter OATP1B1, but not of OATP1B3 and OATP2B1. Genome Med. 2013;5(1):1.
11. Kalliokoski A, Niemi M. Impact of OATP transporters on pharmacokinetics. Br J Pharmacol. 2009;158(3):693-705.
12. Kameyama Y, Yamashita K, Kobayashi K, Hosokawa M, Chiba K. Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells. Pharmacogenet Genomics. 2005;15(7):513-522.
13. Tirona RG, Leake BF, Wolko AW, Kim RB. Human organic anion transporting polypeptide-C (SLC21A6) is a major determinant of rifampin-mediated pregnancy X receptor activation. J Pharmacol Exp Ther. 2003;304(1):223-228.
14. Nozawa T, Minami H, Sugihara S, Tsuji A, Tamai I. Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxy camptothecin: in vitro evidence and effect of single nucleotide polymorphisms. Drug Metab Dispos. 2005;33(3):434-439.
15. Luo JQ, He FZ, Wang ZM, et al. SLCO1B1 Variants and Angiotensin converting enzyme inhibitor (Enalapril) induced cough: a pharmacogenetic study. Sci Rep. 2015;5:17253.
16. Belinder BPS, de With M, Singh RK, et al. The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer. Cancer Chemother Pharmacol. 2020;85(3):547-553.
17. Teo KK, Rafiq T. Cardiovascular risk factors and prevention: a perspective from developing countries. Can J Cardiol. 2021;37(5):733-743.
18. Ortega FB, Lavie CJ, Blair SN. Obesity and cardiovascular disease. Circ Res. 2016;118(11):1752-1770.
19. Andersson C, Vasan RS. Epidemiology of cardiovascular disease in young individuals. Nat Rev Cardiol. 2018;15(4):230-240.
20. Malakar AK, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812-16823.
21. Hamrefors V. Common genetic risk factors for coronary artery disease: new opportunities for prevention? Clin Physiol Funct Imaging. 2017;37(3):243-254.
22. Dittrich J, Beutner F, Teren A, et al. Plasma levels of apolipoproteins C-III, A-IV, and E are independently associated with stable atherosclerotic cardiovascular disease. Atherosclerosis. 2019;281:17-24.
23. Tall AR. Plasma high density lipoproteins: Therapeutic targeting and links to atherogenic inflammation. Atherosclerosis. 2018;276:39-43.
24. Mahley RW. Apolipoprotein E: cholesterol transport protein with expanding role in cell biology. Science (New York, NY). 1988;240(4852):622-630.
25. Choudhary R, Likidilidil A, Peerapatdit T, et al. Apolipoprotein E gene polymorphism: effects on plasma lipids and risk of type 2 diabetes and coronary artery disease. Cardiovasc Diabetol. 2012;11:36.
26. Mahley RW, Rall SC Jr. Apolipoprotein E: far more than a lipid transport protein. Annu Rev Genomics Hum Genet. 2000;1:507-537.
27. Pablos-Méndez A, Mayeux R, Ngai C, Shea S, Berglund L. Association of apo E polymorphism with plasma lipid levels in a multiethnic elderly population. Arterioscler Thromb Vasc Biol. 1997;17(12):3534-3541.
28. Marais AD. Apolipoprotein E in lipoprotein metabolism, health and cardiovascular disease. Pathology, 2019;51(2):165-176.
29. Zhang QH, Yin RX, Gao H, et al. Association of the SPTLC3 rs364585 polymorphism and serum lipid profiles in two Chinese ethnic groups. Lipids Health Dis. 2017;16(1):1.
30. Abuzhalihan J, Adi D, Wang YT, et al. APLP2 gene polymorphisms are associated with high TC and LDL-C levels in Chinese population in Xinjiang, China. Biosci Rep. 2020;40(8). https://doi.org/10.1042/BSR20200357.
31. Agongo G, Amenga-Etego L, Nonterah EA, Pablos-Mendez A, Mayeux R, Ngai C. Association of APOE gene polymorphism with plasma lipid levels and coronary heart disease: A meta-analysis for the Global Burden of Disease Study 2013. Can J Cardiol. 2018;34(3):230-234.
32. Martinez-Magaña JJ, Genis-Mendoza AD. Association between APOE polymorphisms and lipid profile in Mexican American population. Mol Genet Genomic Med. 2019;7(11):e958.
33. Gongor Z, Anuuarad E, Enkhmaa B, Zhang W, Kim K, Berglund L. Apo E4 and lipoprotein-associated phospholipase A2 synergistically increase cardiovascular risk. Atherosclerosis. 2012;223(1):230-234.
34. Shakhtshneider EV, Ragino YI, Chernjavski AM, Kulikov IV, Ivanov MV, Voevod a MI. Apolipoprotein E gene polymorphism in men with coronary atherosclerosis in Siberia. Bull Exp Biol Med. 2011;150(3):355-358.
35. Bennet AM, Di Angelantonio E, Yer Z, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007;298(11):1300-1311.
36. Zhang MD, Gu W, Qiao SB, Zhu EJ, Zhao QM, Lv SZ. Apolipoprotein E gene polymorphism and risk for coronary heart disease in the Chinese population: a meta-analysis of 61 studies including 6634 cases and 6393 controls. PLoS One. 2014;9(4):e95463.
37. Xu M, Zhao J, Zhang Y, et al. Apolipoprotein E gene variants and risk of coronary heart disease: A meta-analysis. Biomed Res Int. 2016;2016:3912175.
38. Larifla L, Armand C, Bangou J, et al. Association of APOE gene polymorphism with lipid profile and coronary artery disease in Afro-Caribbeans. PLoS One. 2017;12(7):e0181620.
39. Griffin B, Walker C, Jebb S, et al. APOE4 genotype exerts greater benefit in lowering plasma cholesterol and apolipoprotein B than wild type (E3/E3), after replacement of dietary saturated fats with low glycaemic index carbohydrates. Nutrients. 2018;10(10):1524.
40. Zhou J, Xue YL, Guan YX, Yang YD, Fu SB, Zhang JC. Association of apolipoprotein E polymorphism with cerebrovascular infarction in type 2 diabetic patients. Hereditas. 2005;47(1):35-38.
41. Liang S, Pan M, Geng HH, et al. Apolipoprotein E polymorphism in normal Han Chinese population: frequency and effect on lipid parameters. Mol Biol Rep. 2009;36(6):1251-1256.
42. Tang H, Yan X, Hua Y, et al. Distribution of apoE polymorphism in Chinese Yunnan Dehong Dai ethnic group. Chin J Med Genet. 2005;22(2):224-226.
43. Wu H, Huang Q, Yu Z, Wu H, Zhong Z. The SNPs rs429358 and rs7412 of APOE gene are association with cerebral infarction but not SNPs rs2306283 and rs4149056 of SLCO1B1 gene in southern Chinese Hakka population. Lipids Health Dis. 2020;19(1):202.
44. Mladenovska K, Grapi AD, Vavluks M, et al. Influence of SLCO1B1 polymorphisms on atorvastatin efficacy and safety in a Macedonian subjects. Pharmazie. 2017;72(5):288-295.
45. Hubacek JA, Dlouha D, Adamkova V, et al. SLCO1B1 polymorphism is not associated with risk of statin-induced myalgia/myopathy in a Czech population. Med Sci Monit. 2015;21:1454-1459.
46. Melo MS, Balcano L, Branco CC, Mota-Vieira L. Genetic variation in key genes associated with statin therapy in the Azores Islands (Portugal) healthy population. Ann Hum Biol. 2015;42(3):283-289.
47. Wu X, Gong C, Weinstock J, et al. Associations of the SLCO1B1 polymorphisms with hepatic function, baseline lipid levels, and lipid-lowering response to simvastatin in patients with hyperlipidemia. Clin Appl Thromb Hemost. 2018;24(9 suppl):2405-2475.
48. Mwinyi J, Köpke K, Schaefer M, Roots I, Gerloff T. Comparison of SLCO1B1 sequence variability among German, Turkish, and African populations. Eur J Clin Pharmacol. 2008;64(3):257-266.
49. Giannakopoulou E, Ragla G, Kolovou V, et al. No impact of SLCO1B1 521T>C, 388A>G and 411G>A polymorphisms on response to statin therapy in the Greek population. Mol Biol Rep. 2014;41(7):4631-4638.
50. Nagy A, Sipeky C, Szalai R, et al. Marked differences in frequencies of statin therapy relevant SLCO1B1 variants and haplotypes between Roma and Hungarian populations. BMC Genet. 2015;16:108.
51. Dendramis G. Interindividual differences in the response to statin therapy and gene polymorphisms related to myopathy during statin therapy. G Ital Cardiol (Rome). 2011;12(3):182-185.
52. Santos PC, Gagliardi AC, Minane MH, et al. SLCO1B1 haplotypes are not associated with atorvastatin-induced myalgia in Brazilian patients with familial hypercholesterolemia. Eur J Clin Pharmacol. 2012;68(3):273-279.
53. Rattanacheeworn P, Chamnanphon M. SLCO1B1 and ABCG2 gene polymorphisms in a Thai population. Pharmgenomics Pers Med. 2020;13:521-530.
54. Na Nakorn C, Waisayarat J, Dejthevaporn C, Srisawasdi P, Wongwaisayawan S, Sukasem C. Genetic variations and frequencies of the two functional single nucleotide polymorphisms of SLCO1B1 in the Thai population. Front Pharmacol. 2020;11:728.
55. Zhong Z, Wu H, Li B, et al. Analysis of SLCO1B1 and APOE genetic polymorphisms in a large ethnic Hakka population in southern China. J Clin Lab Anal. 2018;32(6):e22408.
56. Ghassibe-Sabbagh M, Platt DE, Youhanna S, et al. Genetic and environmental influences on total plasma homocysteine and its role in coronary artery disease risk. Atherosclerosis. 2012;222(1):180-186.
57. Lin R, Wang Y, Wang Y, et al. Common variants of four bilirubin metabolism genes and their association with serum bilirubin and coronary artery disease in Chinese Han population. Pharmacogenet Genomics. 2009;19(4):310-318.
58. Hao F, Lai Y, Dong Y, Yimin DU, Chaoyong M. CYP3A4 and SLCO1B1 genetic polymorphisms in Bai population of Yunnan province. Her Med. 2016;12:78-82.

How to cite this article: Liu Q, Wu H, Yu Z, Huang Q, Zhong Z. APOE gene ε4 allele (388C-526C) effects on serum lipids and risk of coronary artery disease in southern Chinese Hakka population. J Clin Lab Anal. 2021;35:e23925. https://doi.org/10.1002/jcla.23925